MCBÜ Açıkerişim Sistemi :: Browsing by Author "Aydemir Ö."

Browsing by Author "Aydemir Ö."

Now showing 1 - 20 of 89

Benzodiazepines for treatment of depressive disorders; [Depresif bozukluk tanili hastalarda benzodiazepin kullanimi]
(2000) Danaci A.E.; Şen F.S.; Aydemir Ö.; Çelli I.
Object: In conventional publications use of benzodiazepines for treatment of depressive disorders is often recommended as a final chance. In fact, depression implicates symptoms of anxiety as well; anxiety is one of the most frequently encountered symptoms and is among the most sensitive symptoms to show whether depressed patient is getting better or worse. Therefore an effective depression treatment should overcome the anxiety symptoms as well. A period of 2-4 weeks is required in treatment for the effects of antidepressants to start and in clinical practice physicians frequently add other medications to anti-depressants for rapid and additional effects. This study aims to examine the frequency of use of benzodiazepine in treatment of patients with depressive disorder in routine clinical practice. Method: In this study, records of 248 patients who applied to psychiatry outpatient ward of Celal Bayar University Hospital in 1998 and diagnosed with depressive disorder were analyzed. 83.1% of patients were women and 16.9% were men. Diagnostic dispersion was as follows: 65.7% of patients had major depressive disorder, single episode, 2.0% had major depressive disorder, recurrent, 0.8% had bipolar depression, 20.6% had dysthymic disorder and 10.9% had depressive disorder not otherwise specified. Results: 61.7% of patients were prescribed anxiolytic drugs alongside with antidepressant treatment. Use of benzodiazepine in patients with insomnia and anxiety symptoms was statistically higher (P=0.000) when compared to those not having such symptoms. In addition, drop out rates were less with patients having benzodiazepine as a supplement to their routine treatment (p=0.000). Conclussions: This study has shown that use of benzodiazepine in depressed patients, particularly those with anxiety and insomnia symptoms is rather common and this practice enables patients to adapt to treatment better.
Acute exacerbation of positive symptoms in schizophrenia during quetiapine treatment: Five case reports; [Ketiapin saǧaltimi sirasinda şizofreninin pozitif belirtilerinde ortaya çikan akut alevlenme: Beş olgunun sunumu]
(2001) Danaci A.E.; Aydemir Ö.; Içelli I.
Quetiapine is an atypical antipsychotic which has been recently submitted for clinical use in Turkey. Studies revealed that quetiapine is effective on the positive and negative symptoms of schizophrenia and has less side effects compared to conventional antipsychotics. In this article 5 cases, who had been followed with diagnosis of schizophrenia for a long time and had acute exacerbation in positive symptoms during quetiapine treatment, are presented. In literature no articles about side effects of quetiapine were found. The possible reasons of this condition occurring in Turkey was discussed and a study on the pharmacokinetic properties of quetiapine based on this report is proposed.
Relationship of sexuality with psychological and hormonal features in the menopausal period
(2003) Danaci A.E.; Oruç S.; Adigüzel H.; Yildirim Y.; Aydemir Ö.
Women may experience some mental and sexual problems between the ages of 40 years and 60 years due to serious changes in the hormonal system. The aim of this study was to examine the relationships between the changes in sex hormones, sexual behaviours, depression and anxiety levels of women who were in either the premenopausal, perimenopausal or postmenopausal period. The subjects of this cross-sectional study consisted of 324 women who attended the Gynaecology and Obstetrics Out-Patient Ward of Celal Bayar University Hospital. Of this group, 37.0% (n = 124) were postmenopausal, 27.2% (n = 84) perimenopausal and 35.8% (n = 116) premenopausal. Beck Depression Inventory (BDI), State and Trait Anxiety Inventories (STAI-I and II) and a questionnaire on sexual behaviour which was prepared for this study by the authors, were applied to all of the attendees and serum sex hormone levels were analyzed. Beck Depression Anxiety, STAI-I and STAI-II scores and sexual behaviours did not show any statistically significant difference among these three groups. The frequency of sexual intercourse was lower in women with high BDI scores. The rate of painful intercourse was higher in women with high STAI-I scores. The frequency of sexual intercourse, sexual desire and orgasm decreased and painful intercourse increased in women with high STAI-II scores. The frequency of sexual intercourse decreased significantly as the age or follicle stimulating hormone level of women increased. These findings have revealed that the menopausal state did not affect the sexual behaviour, and psychological state of women between the ages of 40 and 60 years, but the increase in anxiety and depression scores affected the sexual life in a negative manner.
Developing a quality of life questionnaire in patients with psoriasis; [Psoriasisli hastalarda yaşam kalite ölçeǧi geliştirilmesi]
(2003) Inanir I.; Aydemir Ö.; Gündüz K.; Danaci A.E.; Ermertcan A.T.
Background and design: Psoriasis is a chronic skin disease which causes psychological, social and physical problems and affecting quality of life. Developing a quality of life instrument for patients with psoriasis which is suitable for our country is aimed in this study. Materials and methods: Twenty five patients with psoriasis, 25 relatives and 25 doctors were questionned about daily life problems caused by psoriasis and the mostly defined problems were collected in an questionnaire. The reliability and validity of this questionnaire were analysed in a group of 156 patients. Results: For reliability, Chronbach's α coefficient was 0.87, and item-total correlations were between 0,37-0,60 in internal consistency. There was a high test-retest reliability (r=0.98, p<0.001). For validity, three factors were extracted in the Principal Components Method in construct validity. The maximum factor loadings of each item were between 0.456-0.681. In convergent validity, all patients' self-ratings and PASI were correlated with the questionnaire score (p<0.001). Conclusion: The questionnaire consisting of 17 items were found to be suitable for both epidemiologic and clinical trials.
Developing a quality of life instrument in patients with psoriasis: The Psoriasis Quality of Life Questionnaire (PQLQ)
(2006) Inanir I.; Aydemir Ö.; Gündüz K.; Esen Danaci A.; Türel A.
Background and design: Psoriasis is a chronic skin disease which causes psychological, social and physical problems and affects quality of life. The aim of this study was to develop a quality of life instrument for patients with psoriasis which is suitable for Islamic populations. Materials and methods: The psychosocial and daily life problems defined by 75 patients with psoriasis, their relatives and physicians were used to construct a questionnaire, the reliability and validity of which were determined in a group of 156 patients with psoriasis. Results: For reliability, Chronbach's α coefficient was 0.87, and item-total correlations were between 0.37 and 0.60 for internal consistency. There was high test-retest reliability (r = 0.98, P < 0.001). For validity, three factors were extracted in the principal components method for construct validity. The maximum factor loadings of each item were between 0.456 and 0.681. For convergent validity, all patients self-ratings and Psoriasis Area and Severity Index (PASI) were correlated with the questionnaire score (P < 0.001). Conclusion: The questionnaire consisting of 17 items was found to be suitable for both epidemiologic and clinical trials. © 2005 The International Society of Dermatology.
Venlafaxine in the treatment of depression in schizophrenia; [Şizofrenide depresyonun venlafaksinle saǧaltimi]
(2006) Esen-Danaci A.; Aydemir Ö.
Objective: Depression in schizophrenia is associated with a poor outcome, an increased risk of relapse and a high rate of suicide therefore it must be treated carefully. Venlafaxine is a dual-action serotonin and noradrenergic reuptake inhibitor and is effective in treating depressive patients. Method: In this study the efficacy and tolerability of venlafaxine is evaluated in 8 schizophrenic patients with depression who used venlafaxine adjunctive to atypical antipsychotics. Results: The patients were assessed with Calgary Depression Scale for Schizophrenia (CDSS), Scale for the Assessment of Positive and Negative Symptoms (SAPS and SANS) at the beginning, 4th week and 8th week. At the end of 8th week of treatment, 2 patients were fully remitted, the other 4 patients showed 80-90% improvement. Total SAPS scores dropped 2 points whereas SANS scores were dropped by 25%. No patients had an adverse event leading to an intervention. Conclusion: Venlafaxine may be an effective and safe alternative in the treatment of depression in schizophrenia.
Prevalence of depressive disorders among patients with fibromyalgia seeking help for the first time and its relationship with alexithymia; [Fizik tedavi ve rehabilitasyon polikliniǧine ilk kez başvuran ve fibromiyalji tanisi konan hastalarda depresif bozukluklarin görülme sikliǧi ve aleksitimi ile ilişkisi]
(2007) Taşkin E.O.; Tikiz C.; Gürlek Yüksel E.; Firat A.; Tüzün Ç.; Aydemir Ö.
Objective: In this study, it was aimed to determine the prevalence of depression and its relationship with alexithymia among patients with fibromyalgia who apply to the Physical Therapy and Rehabilitation outpatient clinic for the first time. Methods: The research included 50 patients who applied to the Physical Therapy and Rehabilitation outpatient clinic for the first time and diagnosed as FM according to the American College of Rheumatology Scale. The subjects were evaluated with the SCID-I affective disorders module, 20-item Toronto Alexithymia Scale (TAS-20), 17-item Hamilton Depression Scale (HAM-D) and a demographic data form. Data were analyzed using t-test for continuous numerical parameters and chi-square test for categorized parameters. Pearson correlation test was used for determination of correlation between HAM-D and TAS-20 scores. Results: The prevalence of major depressive episode, depressive disorder NOS and dysthymia were found to be 44%, 10% and 14% respectively. None of the patients were seeking help for their depressive disorder and were using antidepressant treatment. TAS-20 scores of the patients with depression were higher (p=0.022) than scores of the non-depressive patients. Alexithymic patients had higher HAM-D mean values (p=0.035) and there was a positive correlation between TAS-20 and HAM-D scores (p=0.014). Conclusion: In fibromyalgia, the prevalence rate of depression is found to be significant. The prevalence rate of depression was even higher in alexithymic patients. Patients with fibromyalgia seem to have difficulty in experiencing their depression, and thus they do not seek psychiatric help. Therefore, these patients must be evaluated additionally for depression during the management of fibromyalgia.
Effect of severity of asthma on quality of life
(2007) Şakar A.; Yorgancioǧlu A.; Aydemir Ö.; Sepit L.; Çelik P.
This study is aimed to evaluate the health related quality of life (HRQL) in asthmatics and the probable association between HRQL and disease severity and also other demographic factors by using a generic scale, SF-36 questionnaire. One-hundred and two asthmatics were enrolled. The scores of the 8 domains of SF-36 questionnaire were evaluated according to age, gender, status of education and compared with the severity of asthma. The mean age of 84 (83%) female and 18 (17%) male patients was 42.86 ± 11.15. Fifty-two of them was well educated (51%) and 50 was poorly educated (49%). Atopy ratio was 81%. Mild intermittent, mild persistent and moderate-severe persistent groups were 27 (26%), 46 (45%) and 29 (29%) respectively. Female gender were worse in physical functioning (p= 0.000), physical role difficulties (p= 0.0049), vitality (p= 0.045) and social functioning (p= 0.025). Poorly educated group were worse in physical functioning (p= 0.001), physical role difficulties (p= 0.039), vitality (p= 0.045), emotional role difficulties (p= 0.046), general health (p= 0.030) and mental health (p= 0.044). Mental health was worse in the presence of atopy (p= 0.035). Physical functioning was better in mild intermittent group than moderate and severe persistent group (p= 0.024). General health was better in mild intermittent group than mild persistent group (p= 0.018), moderate and severe persistent group (p= 0.015). Vitality and emotional role difficulties was better in mild intermittent than mild persistent group (p= 0.042, p= 0.007). The HRQL scores and severity of asthma is well correlated like other objective parameters. So one of the primary goals in management of asthma should also improve QOL as well as functional parameters.
Serum brain-derived neurotrophic factor level in dysthymia: A comparative study with major depressive disorder
(Elsevier Inc., 2007) Aydemir Ö.; Deveci A.; Taskin O.E.; Taneli F.; Esen-Danaci A.
In this present work, it is aimed to demonstrate BDNF serum concentrations in patients with dysthymia and to compare them with BDNF serum concentrations in patients with major depressive disorder and healthy subjects. The study was carried out in Celal Bayar University Hospital, Manisa, Turkey. Seventeen patients with dysthymia, 24 patients with major depressive disorder and 26 subjects without any psychiatric diagnosis and any psychiatric treatment were included in the study. The severity of depression was assessed with 17-item HAM-D. All subjects were asked to give their written consent. Blood samples were collected at baseline. Serum BDNF was kept at - 70 °C before testing, and assayed with an ELISA Kit (Promega; Madison, WI, USA), after dilution with the Block and Sample solution provided with the kit. The data were subjected to the analysis of variance. The BDNF serum concentrations of the dysthymia group (mean = 28.9 ± 9.2 ng/ml) were significantly higher than that of the major depressive disorder group (21.2 ± 11.3 ng/ml) (p = 0.002), and it was not different from the level of the control group (31.4 ± 8.8 ng/ml). BDNF serum concentrations and HAM-D score did not have any significant correlation in the dysthymia and major depression groups (r = - 0.276, p = 0.086). The low level of BDNF in patients with dysthymic disorder seems to point out that BDNF changes in mood disorders are state-dependent and vary according to the severity of depressive episodes. © 2007 Elsevier Inc. All rights reserved.
Residual symptoms in bipolar disorder: The effect of the last episode after remission
(2007) Kaya E.; Aydemir Ö.; Selcuki D.
In this study it is aimed to assess interepisode residual symptoms in remitted bipolar disorder patients with a hypothesis that the last episode recovered has implications on residual symptomatology. The study was carried out with 23 bipolar patients diagnosed as mania (BP-M) and 20 bipolar patients diagnosed as depression (BP-D) in their last episode, and with 22 healthy controls in a university hospital clinic. All patients were in remission for at least 6 months. In the assessment Hamilton Depression Rating Scale (HAM-D), Young Mania Rating Scale (YMRS), Stroop Test, Auditory Verbal Learning Test (AVLT), increased latency positive-evoked potentials (P300), Global Assessment of Functioning Scale (GAF), and Social Functioning Scale (SFS) were used cross-sectionally. In affective symptomatology, the BP-M group had higher YMRS scores, and the BP-D group had higher HAM-D scores compared to the controls. P300 test results revealed low amplitude in the BP-D group. In the AVLT, verbal learning and delayed recall were significantly lower in the two bipolar groups. The Stroop tasks were not different in the groups. Concerning the SFS, social withdrawal was impaired in the two bipolar groups, whereas dependency-competency was impaired in the BP-M and employment/occupation was impaired in the BP-D group. As a conclusion, bipolar patients recovering from depressive episode may experience more impairment in daily functioning due to residual depressive symptoms and impairment of attention and memory. © 2007 Elsevier Inc. All rights reserved.
Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression
(Cukurova Univ Tip Fakultesi Psikiyatri Anabilim Dali, 2008) Taşkin E.O.; Aydemir Ö.; Deveci A.; Taneli F.; Selçuki D.; Cerrahoǧlu L.; Danaci A.E.
Objective: In this study, it is aimed to compare the level of Brain-Derived Neurotrophic Factor (BDNF) of patients with migraine and fibromyalgia to that of depressive patients and healthy subjects in order to answer the question whether stress is related to pain syndromes. Methods: In the migraine group 27 patients and in the fibromyalgia group 19 patients without any previous antidepressant treatment and psychiatric diagnosis were included. In the depression group, 24 patients with at least eight weeks of antidepressant-free period were invited to the study. In the depression group no co-morbid diagnosis in the first axis was made. Twenty-six subjects without any previous psychiatric diagnosis and psychiatric treatment consisted the control group. For making diagnosis of depression and other first axis disorders Structured Clinical Interview for DSM- IV (SCID-I) was used in all study groups. For the assessment of the severity of depression Hamilton Depression Rating Scale (HAM-D) was applied. The diagnosis of migraine was made according to the criteria of International Headache Society. For the diagnosis of the fibromyalgia the criteria of American College of Rheumatology was used. The severity of pain was assessed with visual analogue scale (VAS) in the migraine and fibromyalgia groups. Serum BDNF was kept at -70°C before testing, and assayed with an ELISA Kit (Promega; Madison, WI, USA), after dilution with the Block and Sample solution provided with the kit. The data were subjected to Kruskal Wallis Test in the comparison of serum BDNF levels. Results: The serum BDNF level of the depression group (21.2±11.3 ng/ml) was statistically lower (p<0.0001) than the level of the migraine group (32.2±10.1 ng/ml), fibromyalgia group (30.7±8.9 ng/ml) and the control group (31.4±8.8 ng/ml). The level of BDNF was not significantly different in the migraine, fibromyalgia and control groups. There was no significant correlation between serum BDNF levels, and age and gender. In pain syndromes there was no signification correlation between serum BDNF levels, and mean scores of HAM-D and VAS (r= 0.085; p= 0.579 and r= 0.191; p= 0.204 respectively). Similarly there was no significant correlation between serum BDNF levels and HAM-D scores in the depression group (r=0.122; p= 0.579). Conclusions: Even though the pain syndromes were suggested to be associated with stress, in this present work, serum BDNF level as one of the markers of stress does not support this hypothesis. This might be related to the factor that in pain syndromes such as fibromyalgia or migraine, serum BDNF level may be affected by the alteration in peripheral platelet functions. Furthermore in a limited chronic stress serum BDNF levels tend to be not affected and this may play a significant role in our results.
Validity and reliability of the affect underpinned by severity and social impairment questionnaire turkish form; [Duygulanim şddet ve sosyal bozulma ölçeǧi türkçe formu'nun geçerlik ve güvenirliǧi]
(2008) Çetinay P.; Akbay S.; Bilen C.; Gülseren Ş.; Aydemir Ö.
Objective: The aim of this study was to investigate the validity and reliability of the Affect Underpinned by Severity and Social Impairment Questionnaire (AUSSI) Turkish Form. Method: The study included 137 (117 female and 20 male) patients between 18 and 65 years of age who were diagnosed as major depressive disorder according to DSM IV diagnosis. Also 32 control subjects (25 female and 7 male) were included. All subjects completed Sociodemographic Information Form and Affect Underpinned by Severity and Social Impairment Questionnaire. The patients were also assessed by Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS) and Brief Disability Questionnaire (BDQ). For reliability Cronbach's coefficient and split-half reliability analyses were performed. For Validity Analyses, Factor Analyses was performed. Pearson correlation coefficient that between HDRS, HARS, BDQ and AUSSI were also measured. Results: Concerning the reliability of the scale, Cronbach's alpha coefficient was 0.897, Gutman Split-half coefficient was calculated by split half method as 0.862. Cronbach's alpha coefficient composed of 6 items for the first part was 0.801, and for the second part containing the 5 items was 0.857. In order to determine the construct validity of AUSSI, factor analysis was performed using varimax rotation method, and two factors (Affect Severity, Social Impairment) were obtained with Eigenvalue greater than 1.0. Also correlations of AUSSI total between BDQ (r=0.61, p<0.001), HDRS (r=0.74, p<0.001) and HARS (r=0.69 p<0.001) scores were significant. Conclusion: The Turkish version of the Affect Underpinned by Severity and Social Impairment Questionnaire was found to be valid and reliable in this study. AUSSI, allows on a scale to describe mood symptoms and social impairment and to follow up residual symptoms after treatment in patients with major depressive disorder.
BDNF measurement in stress-related mood disorders: A review of clinical studies
(Turkish Association of Nervous and Mental Health, 2009) Aydemir Ö.; Deveci A.
Objective: The study of brain-derived neurotrophic factor (BDNF) in mood disorders and other psychiatric disorders is increasing. Of particular interest is whether or not BDNF can be a marker for psychiatric disorders. The aim of this study was to review the published findings on BDNF in stress-related mood disorders. Method: Searches were conducted of the PubMed and Psikiyatri Dizini databases to access international and national publications, respectively. Database searches were conducted with the keywords BDNF, and stress and mood disorders. Results: BDNF plays a role in the physiopathology of stress-related changes and is supposedly related to a decrease in the number and size of neurons. Additionally, it has been suggested that serum levels of BDNF are lower in depressive patients than in the healthy controls. Nonetheless, BDNF levels increase after antidepressant treatment, along with symptom recovery, to those seen in healthy control subjects. This increase cannot be achieved in patients that do not respond to antidepressant treatment. On the other hand, in patients with stressrelated non-depressive psychiatric disorders, serum BDNF is also low. Conclusion: To date, even though consistent findings of reduced BDNF levels have been reported, the specificity of these findings is doubtful. Serum BDNF might be considered a marker for stress-related mood disorders.
Quality of life in major depressive disorder: A cross-secti onal study
(Turkish Association of Nervous and Mental Health, 2009) Aydemir Ö.; Ergün H.; Soygür H.; Kesebir S.; Tulunay C.
Objective: To investigate quality of life and its association with depression in patients with major depressive disorder. Method: The study included 74 patients diagnosed with major depressive disorder according to DSM-IV. The Hamilton Depression Rating Scale (HAM-D) was used to assess the severity of depression; and the, Medical Outcomes Study Short Form-36 (MOS SF-36) and EuroQol 5-D (EQ-5D) were used to measure quality of life. Results: In the assessment of quality of life, it was determined that Patients with major depressive disorder scored significantly lower on all domains of MOS SF-36 compared to Turkish normative data. The depressive disorder patients had lower EQ-5D health utility index scores, in comparison to Turkish normative data. There was a significant negative correlation between mean HAM-D score and all domains of MOS SF-36 and EQ-5D health utility index scores. When quality of life in depressive patients was compared according to episode type, patients with recurrent type major depressive disorder had lower quality of life in terms of physical functioning, general health perception, and physical component summary score than patients with single episode type major depressive disorder. Concusion: All domains of quality of life were lower in patients with major depressive disorder and quality of life decreased as severity of depression increased. Physical health perception was impaired to a greater degree in patients with recurrent major depressive disorder when compared with single episode depressive patients.
What does the subjective assessment of cognitive functioning measure in bipolar disorder? Correlation with the objective assessment of cognitive functioning
(Turkish Association of Nervous and Mental Health, 2009) Aydemir Ö.; Kaya E.
Objective: Even in remission, cognitive deficits are frequently observed in bipolar disorder. Because these deficits are assessed with complex and comprehensive tests, they seem to be neglected in routine daily practice; however, assessing them with short self-rated questionnaires could be beneficial. This study aimed to investigate the correlation between objective and subjective cognitive assessment in bipolar disorder. Method: The study included 38 patients with bipolar disorder that were in remission for at least 6 months and 19 healthy controls. The Stroop Test and Auditory Verbal Learning Test were used for the objective assessment of cognitive functioning, and the cognitive functioning subscale of the Bipolar Disorder Functioning Questionnaire was used for the subjective assessment of cognitive functioning. Mood symptoms were assessed using the Hamilton Depression Rating Scale and Young Mania Rating Scale. Results: Based on objective assessment there were significant differences in all domains of the Auditory Verbal Learning Test between the bipolar patients and healthy controls, whereas there weren't any significant difference in Stroop Test results. Based on subjective assessment there were significant differences between the bipolar patients and healthy controls in terms of cognitive functioning subscale total score and first item score, but not in terms of the other items. When the correlation between the objective and subjective cognitive assessments was investigated, total score of the cognitive functioning subscale and 2 items-1. to run simple calculations in one's mind and 2. gathering and performing what one is asked to do-were moderately to weakly correlated with immediate recall, verbal learning, recognition, retrieval, and reading shape color. No correlation was observed between the other items of the cognitive functioning subscale. Conclusion: Based on subjective assessment of cognitive functioning, the bipolar patients tended to over-estimate themselves. Furthermore, bipolar patients tended to report more deficits correlated with objective cognitive assessment when they had to display active performance, whereas they did not report cognitive deficits at this level when such a condition was not present.
The validation of Turkish version of personal and social performance scale (PSP); [Bireysel ve sosyal performans ölçeǧi'nin Türkçe sürümünün geçerlilik ve güvenilirlik çalişmasi]
(2009) Aydemir Ö.; Üçok A.; Esen-Danaci A.; Canpolat T.; Karadayi G.; Emiroǧlu B.; Sariöz F.
Objective: Functioning in severe mental disorders is very important and brief functioning rating instruments are needed. Even though patients with severe psychiatric disorders achieve symptomatic recovery, most of them cannot return to their initial level of social functioning. Personal and Social Performance Scale (PSP) is one of the instruments which can be used in severe mental disorders such as schizophrenia and takes a short time to complete. Methods: The study was performed in departments of psychiatry of two university hospitals. In- or out-patients diagnosed with schizophrenia or bipolar disorders were included in the study. The exclusion criteria were comorbidity of other psychiatric disorders including substance use disorders or of physical diseases. For concurrent validity, beside PSP, Clinical Global Impression (CGI), Global Assessment of Functioning (GAF) of DSM-IV, Quality of Life and Satisfaction Questionnaire (QLS-Q), and Positive and Negative Syndrome Scale (PANSS) were used. For discriminant validity, the mean scores of PSP in patients with and without symptomatic remission were compared. Results: The study was carried out with a total of 135 patients, 105 (77.8%) patients diagnosed with schizophrenia and 30 (22.2%) patients diagnosed with bipolar disorder. The mean age of the patients was 34.1±10.7 and 75 (55.6%) of them were male. The duration of illness was 10.4±7.5 years. The mean score of PSP was found to be 60.0±17.1. In the reliability analysis, the Cronbach alpha coefficient was calculated to be 0.8327, and item-total score correlations were found to be between 0.4920-0.7462. Intraclass correlation coefficient was calculated to be 0.8324. The inter-rater reliability of PSP performed on 30 schizophrenic patients was found to be 0.973 (p<0.0001). In the validity analyses, the total score of PSP was significantly correlated with the total score of Clinical Global Impression (CGI) (r=-0.854, p<0.0001), Global Assessment of Functioning (GAF) (r=0.748, p<0.0001), Quality of Life and Satisfaction Questionnaire (QLS-Q) (r=0.734, p<0.0001), and Positive and Negative Syndrome Scale (PANSS) (r=-0.664, p<0.0001). There was a significant difference between the patients with and without symptomatic remission (54.8±14.8 vs. 72.6±9.8, t=7.434, p<0.0001). Conclusion: The Turkish version of PSP was found to be reliable and valid in severe mental disorders and was sensitive to change. It can be used both in clinical trials and routine clinical practice.
Functioning in schizophrenia and paliperidone: A review of studies with personal and social performance scale; [Şizofrenide işlevsellik ve paliperidon: Bireysel ve toplumsal performans ölçeǧi ile yapilan çalişmalarin gözden geçirilmesi]
(2009) Aydemir Ö.
Even though the relief of symptoms can be achieved with the treatments used in schizophrenia, the re-gain of the functioning cannot be established to that extent. Patients can have difficulties in the social adaptation, impairment in interpersonal relations, problems in family communication, difficulties in occupational functioning, and inadequacy in self-care. Personal and Social Performance Scale (PSP) is a comprehensive and sensitive to change instrument developed for the assessment of social functioning in schizophrenia. Paliperidone provides significant remission in social functioning assessed with PSP. The pooled data of the three clinical trials with paliperidone are re-analyzed. In the analyses, paliperidone 3 mg provided an improvement of 8.3±17.1 in the PSP score, for 6 mg it is 9.0±14.8, for 9 mg 7.8±14.3, for 12 mg 9.5±15.0, and for 15 mg it is 12.2±15.7. With placebo, the reduction in the PSP score is 0.5±15.0. When the improvement of at least one category (i.e. one ten-point interval) is taken into consideration, 50.4% of the patients in the treatment of 3 mg of paliperidone, 56.1% in the 6 mg group, 49.6% in the 9 mg group, 54.1% in the 12 mg group and 63.6% in the 15 mg group achieved improvement. Patients in the paliperidone group improved significantly in social functioning when compared with patients in the placebo group. In acute schizophrenia with six-week treatment, paliperidone appears to be effective in the improvement of impairment in social functions.
Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study
(2009) Esen-Danaci A.; Aydemir Ö.; Deveci A.; Taneli F.; Taşkin O.
Objectives: Evidence from clinical, pharmacological and animal studies, have led to neurodevelopment, neurodegeneration, and dopamine hypotheses, and to the investigation of BDNF as a potential candidate molecule in the pathophysiology of schizophrenia. The aim of this study is to investigate the BNDF levels of schizophrenic patients with depression and compare them with major depression patients and controls in order to understand the nature of depressive symptoms seen in schizophrenia. Methods: The BDNF levels of eight schizophrenic patients with depressive symptomatology (SD) were compared with two control groups. The first group consisted of major depressed patients (MDD) (n=24) and the second was the healthy control group (n=26). Results: SD group had BDNF levels similar to control group and MDD group had significantly lower levels than the other two groups. Conclusion: This difference of BDNF levels between schizophrenia with depression group and major depression group supports the hypothesis of distinct etiologies.
Attention deficit and hyperactivity symptoms in children with monosymptomatic nocturnal enuresis; [Monosemptomatik nokturnal enürezisi olan çocuklarda dikkat eksikliǧi ve hiperaktivite bulgulari]
(Kare Publishing, 2010) Ertan P.; Gönülal D.; Söǧüt A.; Yilmaz Ö.; Bozgül A.; Dinç G.; Aydemir Ö.; Yüksel H.
Aim: Monosymptomatic nocturnal enuresis in children may cause psychological and behavioral problems. The aim of this study was to assess symptoms of attention deficit and hyperactivity in children with monosymptomatic nocturnal enuresis. Material and Method: Fifty-seven children (23 male, 34 female) with monosymptomatic nocturnal enuresis and 57 healthy controls (25 male, 32 female) aged 6 to 12 years participated in the study. Conners' Parent Rating Scale-48 (CPRS), a 48-item multiple-choice questionnaire, was completed by the mothers to identify the attention deficit and hyperactivity symptoms in children. Results: Mean age of the children with enuresis was 8.54±2.18 years and that of the control group 9.12±2.13 years. Attention deficit score in the enuretic group was significantly higher than that in the control group (p=0.02). Hyperactivity scores were not significantly different between the groups (p=0.36). Bedwetting frequencies were not different between enuretic children with and without attention deficit or hyperactivity symptoms (p=0.06). Conclusions: Psychological and behavioral assessment may be indicated in children with monosymptomatic nocturnal enuresis since the results of this study demonstrate increased attention deficit symptomatology.
Reliability and validity of Turkish version of COPD Assessment Test; [KOAH deǧerlendirme testinin Türkçe geçerlilik ve güvenilirliǧi]
(Ankara University, 2012) Yorgancioǧlu A.; Polatli M.; Aydemir Ö.; Yilmaz Demirci N.; Kirkil G.; Nayci Atiş S.; Köktürk N.; Uysal A.; Akdemir S.E.; Özgür E.S.; Günakan G.
Introduction: This study is aimed to evaluate the reliability and validity of the Turkish version of chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) in seven centers. Materials and Methods: 321 patients between 4-75 years of age, diagnosed and staged by Global Initiative for Obstructive Lung Disease (GOLD) 2011 criteria were included. The Breathlessness, Cough, Sputum scale (BCSS), mMRC (Modified Medical Research Council) dyspnea index, St. George Respiratory Questionnaire (SGRQ), CAT and Short Form-36 (SF-36) were used concurrently. In the statistical analyses, internal consistency, item-total score correlation, explorative factor analysis, correlation with other scales were calculated. Results: The mean age was 62.4 ± 8.9 years and 89.7% of the patients were male (n= 288). Mean FEV 1% was 51.9 ± 19.2 and most of the patients were in Stage 3. CAT total score was 17.8 ± 9.5. In the internal consistency, Cronbach alpha coefficient was found as 0.9116 and item-total score correlation coefficients were between 0.62-0.79 and all were statistically significant (p< 0.0001). The correlation of the test-retest score calculated after two weeks with the initial score was 0.96 (p< 0.0001). In the structural validity, factor analysis with principle component analysis and varimax rotation was performed. One factor solution was achieved with eigenvalue of 4.956 and it represented 61.9% of the total variance. All the items were contained in the factor and the factor loads were between 0.71-0.85. The correlation coefficients of CAT with other indexes were moderate to good. The discrimination of CAT among disease stages has been shown to be significant (p< 0.0001) and a significant correlation was found with pulmonary function tests (p< 0.0001). Conclusion: It is demonstrated The Turkish version of COPD Assessment Tool is reliable and valid.

Browsing by Author "Aydemir Ö."

Results Per Page

Sort Options